Literature DB >> 30149246

Individual results may vary: Inequality-probability bounds for some health-outcome treatment effects.

John Mullahy1.   

Abstract

While many results from the treatment-effect and related literatures are familiar and have been applied productively in health economics evaluations, other potentially useful results from those literatures have had little influence on health economics practice. With the intent of demonstrating the value and use of some of these results in health economics applications, this paper focuses on one particular class of parameters that describe probabilities that one outcome is larger or smaller than other outcomes ("inequality probabilities"). While the properties of such parameters have been exposited in the technical literature, they have scarcely been considered in informing practical questions in health evaluations. This paper shows how such probabilities can be used informatively, and describes how they might be identified or bounded informatively given standard sampling assumptions and information only on marginal distributions of outcomes. The logic of these results and the empirical implementation thereof-sampling, estimation, and inference-are straightforward. Derivations are provided and several health-related applications are presented.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inequality probabilities; Probability bounds; Treatment effects

Mesh:

Year:  2018        PMID: 30149246      PMCID: PMC6588285          DOI: 10.1016/j.jhealeco.2018.06.011

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  19 in total

1.  Generalized treatment effects for clinical trials.

Authors:  W W Hauck; T Hyslop; S Anderson
Journal:  Stat Med       Date:  2000-04-15       Impact factor: 2.373

2.  On the construction of bounds in prospective studies with missing ordinal outcomes: application to the good behavior game trial.

Authors:  Daniel O Scharfstein; Charles F Manski; James C Anthony
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

3.  Value-Based Payments Require Valuing What Matters to Patients.

Authors:  Joanne Lynn; Aaron McKethan; Ashish K Jha
Journal:  JAMA       Date:  2015-10-13       Impact factor: 56.272

4.  A median voter model of health insurance with ex post moral hazard.

Authors:  Johanna Jacob; Douglas Lundin
Journal:  J Health Econ       Date:  2004-12-25       Impact factor: 3.883

5.  Assessing the impact of high deductible health plans on health-care utilization and cost: a changes-in-changes approach.

Authors:  Bijan J Borah; Marguerite E Burns; Nilay D Shah
Journal:  Health Econ       Date:  2011-06-01       Impact factor: 3.046

6.  Inequality in treatment benefits: Can we determine if a new treatment benefits the many or the few?

Authors:  Emily J Huang; Ethan X Fang; Daniel F Hanley; Michael Rosenblum
Journal:  Biostatistics       Date:  2017-04-01       Impact factor: 5.899

7.  Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation.

Authors:  R I Horwitz; B H Singer; R W Makuch; C M Viscoli
Journal:  J Clin Epidemiol       Date:  1996-04       Impact factor: 6.437

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

Review 10.  From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer.

Authors:  Richard J Willke; Zhiyuan Zheng; Prasun Subedi; Rikard Althin; C Daniel Mullins
Journal:  BMC Med Res Methodol       Date:  2012-12-13       Impact factor: 4.615

View more
  1 in total

1.  Discovering treatment effectiveness via median treatment effects-Applications to COVID-19 clinical trials.

Authors:  John Mullahy
Journal:  Health Econ       Date:  2021-03-05       Impact factor: 3.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.